Background {#Sec1}
==========

Type 2 diabetes mellitus (T2DM) is a recognized risk factor for coronary atherosclerosis and subsequent cardiovascular events which results in a two- to threefold higher mortality risk compared to patients without T2DM \[[@CR1], [@CR2]\]. Several investigations have indicated that T2DM patients without a history of cardiovascular events have a similar chance for myocardial infarction as compared to non-T2DM patients with previous coronary events \[[@CR2], [@CR3]\]. Cardiovascular events usually arise from rupture of a vulnerable, coronary plaque \[[@CR4]\]. We and others have demonstrated using optical coherence tomography (OCT), that coronary lesions of patients with T2DM are characterized by several features of plaque vulnerability, including a higher frequency of thin-capped fibroatheromas (TCFA), a larger lipid core, the presence of microvessels and/or macrophages suggesting coronary inflammation \[[@CR5], [@CR6]\].

Recently, coronary calcification has been discussed as an additional risk factor of coronary plaque vulnerability. Specifically, investigations using computed tomography and intravascular ultrasound (IVUS) have indicated that the extent of coronary calcification generally correlates with atherosclerotic plaque burden as well as with the incidence of adverse cardiac events \[[@CR7]\]. Furthermore, superficial microcalcifications may be responsible for a higher tissue stress \[[@CR8], [@CR9]\] and thus may induce a higher rate of cardiovascular events \[[@CR9]--[@CR11]\]. Moreover, calcified nodules, defined as calcifications protruding into the lumen with an overlying fibrous cap disruption, may be a novel morphological feature causing an acute coronary syndrome (ACS) \[[@CR12]\]. Taken together, the contribution of plaque calcification to plaque vulnerability appears to be dependent on presence, size and localization of calcifications within lesions. To date, the impact of T2DM on these parameters is unknown. Due to its superior resolution of approximately 10--20 µm, OCT allows a supreme "in vivo" visualization of different plaque morphologies as well as a precise quantification of coronary luminal and intraluminal parameters \[[@CR13]\]. Given that particularly small and superficial calcifications contribute to lesion vulnerability, OCT presently represents the most accurate method to determine localization, size, shape and extent of calcifications within coronary lesions in vivo \[[@CR14]\].

Due to the enhanced cardiovascular event rate of patients with T2DM, the aim of this study was to compare differences of coronary plaque morphology in patients with and without T2DM by OCT. As micro-calcifications are a novel feature of coronary plaque vulnerability, this study investigated if the increased cardiovascular risk of patients with T2DM may be explained by an altered localization, size, shape or extent of calcifications within coronary lesions.

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

In this study, 98 patients with stable coronary artery disease (CAD) and 112 de novo coronary target lesions were examined with coronary angiography and coronary OCT-analysis prior to coronary intervention at the Department of Cardiology of the University Hospital of the RWTH Aachen between July 2014 and January 2017. All patients underwent coronary angiography due to stable CAD. Main inclusion criterion was the presence of a coronary stenosis suitable for OCT analyses, in which the OCT examination itself demonstrated the presence of calcification. Of the initial 98 patients with 112 lesions included in the study, 7 patients with 7 lesions were excluded due to the absence of calcification in the OCT-analysis, resulting in 105 lesions from 91 patients. The study cohort was divided into a diabetic (56 patients, 56 lesions) and non-diabetic group (35 patients, 49 lesions, Fig. [1](#Fig1){ref-type="fig"}). This number of patients has previously been sufficient to show differences in OCT-derived plaque morphology including plaque calcification between patients with and without diabetes \[[@CR15]\]. The diagnosis of T2DM was based on clinical history, ongoing antidiabetic therapy and/or an Hb~A1C~ \> 6.5%. Stable CAD at the time of intervention was defined as no progression of severity, frequency and duration of clinical symptoms within the previous 6 weeks. Target lesion identification was based on the coronary angiogram with an at least 40% stenosis suitable for coronary intervention and confirmed by the combination of echocardiographic wall motion abnormalities, positive stress testing in MRT or echocardiography and/or evidence of hemodynamic relevance of the coronary lesion as assessed by fractional flow reserve (FFR) measurements. The presence of significant myocardial ischemia and not plaque morphology/vulnerability was used to guide coronary intervention.Fig. 1Study design algorithm including inclusion and exclusion criteria is depicted. ACS, acute coronary syndrome; CAD, coronary artery disease; OCT, optical coherence tomography

Exclusion criteria were left main coronary artery stenosis, bifurcation and bypass graft lesions, in-stent restenosis, an ongoing ACS, an acute or chronic renal insufficiency and pregnancy. Written informed consent of all patients was obtained. The study was approved by the local ethics committee and is in accordance with the declaration of Helsinki on ethical principles for medical research involving human subjects.

Image acquisition {#Sec4}
-----------------

The OCT images in the target lesions were acquired using a Frequency-Domain-OCT C7XR system and the DragonFly catheter (St. Jude Medical Systems; Lightlab Imaging, Inc, Westford, Massachusetts, USA). Complete blood removal as a prerequisite for image acquisition using the infrared light technique of OCT was obtained by the injection of 14 ml contrast (iodixanol) at a flow rate of 4 ml/s through the guiding catheter. The image acquisition was obtained with an automated pull-back at a rate of 20 mm/s. The following offline plaque analysis was performed by two independent observers with an extensive experience in OCT imaging analysis\[[@CR16]--[@CR20]\], blinded to the study protocol. The analysis was carried out throughout the entire lesion frame by frame in 0.4 mm intervals using St. Jude's proprietary software. In case of discordant results a consensus measurement was taken. The intraclass correlation coefficients for intra- and interobserver agreements were 0.979 and 0.893 for calcium arc, 0.989 and 0.902 for calcium area and 0.949 and 0.927 for percent area stenosis.

Morphological analysis {#Sec5}
----------------------

The OCT image analysis was performed over the entire segment of the pull-back image (54 mm). The morphological and quantitative intraluminal analysis of the plaque was performed as previously described by Tearney et al. \[[@CR21]\]. The presence of calcified (signal-poor heterogeneous region with clearly delineated contours) and lipid (signal-poor homogeneous region without borders and high signal attenuation) regions were assessed. Two calcifications were considered as parted when they were longitudinally separated by at least 1 mm or when they were detectable on different portions of the single slice image without any contact or continuity throughout the whole length of the calcifications themselves.

Analysis of each calcified region by OCT consisted of the measurement of the following parameters and as displayed in Fig. [2](#Fig2){ref-type="fig"}:Fig. 2Details of calcification analysis in short (**a**) and long axis (**b**). Quantitative analysis of various parameters for the assessment of localization, size, shape and extent of calcifications in a transverse (**a**) and longitudinal (**b**) section of an OCT---image of a fibrocalcific coronary plaque Calcium arc, defined as the widest angle in which the calcifications were detectable;calcium depth, defined as the distance between the most superficial edge of calcification and the vessel lumen;calcium thickness, defined as the maximal diameter of the calcification, measured perpendicularly to the lumen/intima interface;calcium area, measured manually following the sharply delineated contour of each calcium deposit. In case the contour was partly not detectable, the automatic interpolation function of the analytic software was used;calcium length, defined as the total length of calcifications in the whole plaque;calcium index, defined as the product of the mean calcium arc and the total calcium length, as previously described by Ong et al. \[[@CR22]\].

In analogy to previous intravascular imaging studies assessing coronary calcifications \[[@CR23]--[@CR25]\], each plaque was furthermore characterized and classified according to the maximal calcium angle as:Spotty calcification, defined as a calcium length \< 4 mm and a maximal calcium angle ranging from 22.5° to 90°;macrocalcification, characterized by a maximal calcium angle \> 90°;microcalcification, in case of a maximal calcium angle \< 22.5° and a maximal calcification length \< 1 mm.

Due to the absence of established OCT criteria defining superficial calcifications and in analogy to a previous study from Ong \[[@CR22]\], we defined single deposits as superficial-65 and superficial-100 according to their minimal calcium depth ≤ 65 or ≤ 100 µm, respectively.

Statistical analysis {#Sec6}
--------------------

All statistical analyses were performed with SPSS software (IBM Corp., Armonk, NY, USA). Binary variables were summarized as count (percentage), continuous variables as mean ± standard deviation. The data were analyzed both on a per-patient basis for clinical characteristics and on a per-stenosis basis for lesion morphology. The statistical test did not account for the correlation of multiple plaques within patients. Distributions of continuous variables were compared with *t* test. Binary variables were compared by Pearson's Chi squared test.

To account for possibly confounding differences between patients in localization, size, shape or extent of calcifications within coronary lesions with and without diabetes, covariate adjusting to the propensity score was performed. The propensity score was calculated using a multivariable binary logistic regression analysis with sex, age, mean arterial pressure, body mass index, total pack years and LDL-cholesterol as covariates. Covariate adjusting to the propensity score was performed using multivariable binary logistic regression analysis for binary variables or multivariable linear regression analysis for continuous variables. Statistical significance was awarded for p \< 0.05.

Results {#Sec7}
=======

Study population {#Sec8}
----------------

The 105 analyzed calcified lesions from 91 patients were categorized into two groups of 56 lesions from 56 patients with T2DM and 49 lesions from 35 patients without T2DM. Regarding cardiovascular risk factors, patients with T2DM showed a significantly higher body mass index (30.87 ± 4.58 kg/m^2^ vs. 27.75 ± 4.25 kg/m^2^, p \< 0.001) and a higher rate of hyperlipidemia (69.65% vs. 45.71%, p = 0.04), whereas patients without T2DM presented with a higher cumulative tobacco exposure (32.71 ± 34.39 vs. 17.09 ± 22.19 pack years, p \< 0.001). However, the quantitative number of active smokers at the time of study inclusion did not differ significantly (25.71% vs. 16.07%, p = 0.26). Further clinical characteristics of the two groups are reported in Table [1](#Tab1){ref-type="table"}.Table 1Population analysisNon DM (35)DM (56)p valueSex (male, %)28 (80.0)36 (64.3)NSAge (years)70.7 ± 9.470.4 ± 5.9NSMAP (mmHg)97 ± 1296 ± 12NSBMI (kg/m^2^)27.7 ± 4.230.9 ± 4.6\< 0.001Positive family history (n, %)17 (48.6)25 (44.6)NSHistory of hypertension (n, %)30 (85.7)49 (87.5)NSHyperlipidaemia (n, %)16 (45.7)39 (69.6)0.04Current smoking (n, %)9 (25.7)9 (16.1)NSTotal pack years32.7 ± 34.417.1 ± 22.2\< 0.001COPD (n, %)3 (8.6)6 (10.7)NSKnown CAD (n, %)12 (34.3)20 (35.7)NSPrevious PCI (n, %)11 (31.4)14 (25.0)NSPrevious CABG (n, %)1 (2.9)2 (3.6)NSAngina (CCS class)1.9 ± 1.12.3 ± 0.7NSDyspnoe (NYHA class)1.6 ± 1.12.1 ± 0.8NSDuration of diabetes (years)NA11.9 ± 9.4NADiabetic retinopathy (n, %)NA10 (17.9)NADiabetic polyneuropathy (n, %)NA20 (35.7)NATotal cholesterol (mg/dl)195.3 ± 43.8191.2 ± 45.1NSLDL-cholesterol (mg/dl)128.9 ± 39.6117.8 ± 36.4NSHDL-cholesterol (mg/dl)48 ± 13.244.2 ± 10.3NSHbA1c (%)5.7 ± 0.47.2 ± 1.6\< 0.001Medication prior to coronary angiography ASA (n, %)31 (88.6)52 (92.9)NS ACEi/ARB (n, %)24 (65.7)40 (71.4)NS β-Blocker (n, %)24 (65.7)46 (82.1)NS Statine (n, %)21 (60.0)35 (62.5)NSThe data are presented as mean ± SD or n (%) and displayed with p valuesDM, diabetes mellitus; BP, blood pressure; MAP, mean arterial pressure; BMI, body mass index; COPD, chronic obstructive pulmonary disease; CAD, coronary artery disease; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; CCS, Canadian Cardiovascular Society; NYHA, New York Heart Association; LDL, low density lipoprotein, HDL, high density cholesterol; ASA, acetylsalicylic-acid; ACEi/ARB, angiotensin converting enzyme inhibitors/angiotensin receptor blockers; NS, not significant; NA, not applicable

Extent and morphology of calcification {#Sec9}
--------------------------------------

In both, patients with and without T2DM, a similar amount of calcifications within the coronary target vessel was detected. Similarly, the amount of micro- (0.34 ± 0.79 vs. 0.31 ± 0.71), spotty (2.11 ± 1.77 vs. 2.37 ± 1.89) or macro-calcifications (1.55 ± 1.13 vs. 1.53 ± 0.71) did not differ significantly between the diabetic and non-diabetic group. However, a significantly higher frequency of spotty calcifications could be found in patients without T2DM (93.90%) compared to those with T2DM (78.57%, p = 0.025). Furthermore, no significant difference was found in the measurements of the remaining parameters which quantitatively and morphologically assessed calcification in the two groups. A non-significant trend in favor of a higher mean and maximal calcified area was detected in patients with T2DM (respectively 0.99 ± 0.72 mm^2^ vs. 0.78 ± 0.49 mm^2^, p = 0.085 and 2.82 ± 2.01 mm^2^ vs. 2.18 ± 1.76 mm^2^, p = 0.085). No differences between patients with and without T2DM were detected in the number of superficial calcifications (superficial-65: 1.93 ± 1.64 vs. 2.06 ± 2.07; superficial-100: 2.37 ± 1.90 vs. 2.65 ± 2.63, all p = ns) or in the percent of superficial calcifications among the total number of deposits (superficial-65: 49.4 ± 34.3% vs. 44.6 ± 33.8%; superficial-100: 59.8 ± 34.7% vs. 57.1 ± 36.1%, all p = ns).

To analyze if the impact of type 2 diabetes on localization, size, shape or extent of calcifications within coronary lesions may be balanced by the potential effect of other clinical and laboratory parameters, covariate adjusting to the propensity score was performed. However and as depicted in Table [2](#Tab2){ref-type="table"}, presence of type 2 diabetes was not associated with significant differences in parameters describing localization, size, shape or extent of calcifications within coronary lesions. Further details are depicted in Table [2](#Tab2){ref-type="table"}.Table 2OCT-derived analysis of extent and morphology of calcificationNon DM (49)DM (56)p valuep value\*Microcalcifications (present, %)10 (20.4)11 (19.6)NSNSMicrocalcifications (n per lesion)0.3 ± 0.70.3 ± 0.8NSNSSpotty calcifications (present, %)46 (93.9)44 (78.6)0.025NSSpotty calcifications (n per lesion)2.4 ± 1.92.1 ± 1.8NSNSMacrocalcifications (present, %)34 (69.4)46 (82.1)NSNSMacrocalcifications (n per lesion)1.5 ± 0.71.5 ± 1.1NSNSTotal no. of calcifications (n)4.2 ± 3.14.0 ± 2.6NSNSSuperficial65 calcifications (n per lesion)2.1 ± 2.11.9 ± 1.6NSNSSuperficial65 calcifications (% of total calcifications)44.6 ± 33.849.4 ± 34.3NSNSSuperficial100 calcifications (n per lesion)2.7 ± 2.62.4 ± 1.9NSNSSuperficial100 calcifications (% of total calcifications)57.1 ± 36.159.8 ± 34.7NSNSMean calcium arc (°)73.7 ± 31.682.3 ± 44.8NSNSMean thickness of calcification (mm)0.5 ± 0.10.5 ± 0.1NSNSMaximal thickness of calcification (mm)0.9 ± 0.31.0 ± 0.3NSNSMean depth of calcification (µm)160 ± 76172 ± 192NSNSMinimal depth of calcification (µm)62 ± 6150 ± 71NSNSMean calcified area (mm^2^)0.8 ± 0.51.0 ± 0.70.085NSMaximum calcified area (mm^2^)2.2 ± 1.82.8 ± 2.00.085NSCalcium length (mm)12.2 ± 9.813.6 ± 8.9NSNSCalcium index (° × mm)1016 ± 9581311 ± 1312NSNSThe data are presented as mean ± SD or n (%). Abbreviations as in Table [1](#Tab1){ref-type="table"}. Superficial65 and Superficial100 calcifications have a minimal depth of 65 and 100 μm, respectively, as defined in the "[Methods](#Sec2){ref-type="sec"}" section. The data is displayed with p values; p values\* are adjusted to the propensity score

Further characteristics of plaque morphology {#Sec10}
--------------------------------------------

In the patient cohort with T2DM, a lower minimal fibrous cap thickness (FCT) (80.4 ± 27.0 µm vs. 106.8 ± 27.8 µm, p \< 0.00001) and a significantly higher percent area stenosis (77.9 ± 8.1% vs. 71.7 ± 11.2%, p \< 0.01) was detected, as shown in Fig. [3](#Fig3){ref-type="fig"} and Table [3](#Tab3){ref-type="table"}. Non-significant trends towards a lower mean FCT (125.7 ± 27.0 µm vs. 142.5 ± 27.8 µm, p = 0.07) and a lower mean lipid arc (121.5 ± 40.5° vs. 148.5 ± 50.0°, p = 0.054) were demonstrated in patients with T2DM compared to patients without T2DM. The above described differences in minimal FCT and percent area stenosis remained significant even when co-variates were adjusted to the propensity score (Table [3](#Tab3){ref-type="table"}).Fig. 3Lipid plaques in patients with (**b**) and without diabetes (**a**). In the presence of diabetes a thinner minimal fibrous cap thickness can be identified. In (**a**) a spotty calcification is visible (marked with the yellow arrow). FCT, fibrous cap thickness Table 3OCT-derived analysis of further plaque morphology characteristicsNon DM (49)DM (56)p valuep value\*Length of stenosis (mm)7.7 ± 5.58.5 ± 5.7NSNSPercent area stenosis (%)71.7 ± 11.277.9 ± 8.10.0010.019Minimal FCT (µm)106.8 ± 27.880.4 ± 27.0\< 0.0010.031Mean FCT (µm)142.5 ± 27.8125.7 ± 27.00.070NSMean lipid arc (°)148.5 ± 50.0121.5 ± 40.50.054NSThe data are presented as mean ± SD. Abbreviations as in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}. FCT, fibrous cap thickness. The data is displayed with p values; p values\* are adjusted to the propensity score

Discussion {#Sec11}
==========

The main findings of this OCT-investigation are:Coronary lesions in patients with T2DM are associated with a lower minimal FCT suggesting a more vulnerable plaque phenotype of the target lesion compared to patients without T2DM.There are no significant or relevant differences, neither quantitatively nor qualitatively, regarding localization, size, shape or extent of calcifications in T2DM patients compared to non-diabetics.

Despite recent advances in diagnosis and treatment of atherothrombosis, CAD remains the leading cause of morbidity and mortality in the Western population. Thus, early identification of patients at high cardiovascular risk is necessary. With the emerging use of intracoronary imaging techniques, clinicians have gained more insights into coronary plaque morphology. We and others have previously demonstrated that established features of plaque vulnerability such as a thin fibrous cap overlying the necrotic lipid core, the size of the necrotic lipid core and the presence of macrophages can be visualized in vivo with OCT \[[@CR6], [@CR26]\]. These features are often present even in patients with clinically stable CAD \[[@CR26]\], thus probably marking a subpopulation at high risk for a future ACS.

It has recently been suggested that localization, size, shape or extent of calcifications within coronary lesions may represent an additional risk factor of coronary plaque vulnerability. Pen et al. \[[@CR27]\] demonstrated that patients with a high Framingham risk score have a significantly higher prevalence of coronary calcification compared to those with a low Framingham risk score. Vice versa, the calcium score correlates positively with the incidence of cardiovascular events \[[@CR7]\].

With regard to the morphology of calcifications, Vengrenyuk et al. have demonstrated that small superficial calcifications may significantly increase the stress on the fibrous cap; for example, the same fibrous cap stress (300 kPa) in a homogeneous fibrous cap with a thickness of only 65 µm may also be reached in presence of a single, small superficial inclusion in a fibrous cap with a thickness of 200 µm \[[@CR9]\]. These data suggest that the inclusion of micro-calcifications within a fibrous cap may mechanically destabilize the fibrous cap and furthermore result in a more vulnerable type of coronary lesion. However, previous studies investigating the localization, size, shape or extent of calcifications used either computed tomography (CT) or IVUS, which are both limited by a lower resolution compared to OCT \[[@CR28]\]. Moreover, OCT offers a supreme and established definition of relevant features of vulnerable lipid plaques, such as the minimal FCT, the presence of TCFAs, macrophages, microchannels as well as small calcium deposits \[[@CR15], [@CR29]\]. Furthermore, OCT is also effective for the quantification of calcium burden, showing a better correlation with histological assessments compared to IVUS \[[@CR14]\]. In addition, OCT is very sensitive to detect superficial calcification and can provide detailed information of calcification morphology, even though it is sometimes difficult to contour calcification shape for deep calcification in certain cases because of the poor penetration of OCT.

As particularly small, superficial calcifications may have an impact on plaque vulnerability, the need for a more precise analysis, exploiting the superior resolution of OCT, has emerged recently. We and others have previously shown that patients with T2DM yield a more vulnerable phenotype of coronary plaques, which may contribute to the higher frequency of cardiovascular events in this population \[[@CR6], [@CR30], [@CR31]\]. Part of this vulnerable phenotype may be reverted through statin use, as the OCT-FORMIDABLE register suggests \[[@CR32]\], and this effect seems to be enhanced by an optimal glucose control in the diabetic population \[[@CR33]\]. The direct, prospective impact of these morphological features on cardiovascular events is currently being analyzed by the ongoing COMBINE study \[[@CR34]\]. As micro-calcifications are novel features of coronary plaque vulnerability, our study investigated if the increased cardiovascular risk of patients with T2DM can be explained by an altered localization, size, shape or extent of calcifications within coronary lesions. In the present investigation we extend the current knowledge by demonstrating that patients with T2DM exhibit no significant differences in calcium burden or morphology when compared to patients without T2DM, and these results remained the same following co-variate adjustment to the propensity score. These data are surprising as a recent meta--analysis \[[@CR30]\] demonstrated, that in symptomatic patients without known CAD, calcifications assessed through CT scans are more frequent in patients with T2DM. In this study, T2DM seems to be a relevant risk factor for "severe calcification", but not for mild calcification \[[@CR30]\]. Similarly, the MESA Study demonstrated a higher calcium burden in patients with T2DM \[[@CR35]\] and Kim et al. pointed out a higher calcium score and a more rapid progression of coronary calcification in patients with metabolic syndrome \[[@CR36]\]. However, all of these studies enrolled patients without previously known CAD and performed an image analysis throughout the whole coronary system. Thus, the difference between those investigations and our study may refer to the different study population, study design and imaging modality.

To date only few studies assessed intravascular calcification using the OCT-technique. Krishnamoorty et al. reported a reduced overall calcium volume in the target lesion of patients with T2DM and the authors hypothesized that T2DM might be related to small calcifications with a spotty distribution pattern \[[@CR37]\]. On the other hand, a study by Kato et al. \[[@CR15]\] showed a higher rate of coronary calcification in patients with T2DM without further detailed and quantitative analysis regarding calcification. In our study, however, we did not observe any difference in localization, size, shape or extent of calcifications using a complex and quantitative frame-by-frame analysis which also assessed the pattern of calcification in detail. In addition, we found a lower minimal FCT and a higher percent area stenosis in patients with T2DM, which is in line with previous studies \[[@CR15], [@CR31], [@CR38]\], suggesting a more vulnerable plaque phenotype in patients with T2DM.

Taken together, in the light of our data it is tempting to speculate that the enhanced cardiovascular risk of patients with T2DM cannot be explained by an altered localization, size, shape or extent of calcifications but rather by an altered minimal FCT.

Limitations {#Sec12}
-----------

There are several limitations to this study that need to be addressed. Although OCT allows a reliable and effective quantification of calcification \[[@CR14]\] and the parameters used to assess localization, size, shape or extent of calcifications are in analogy to the established quantification of the necrotic lipid core, they still need to be validated in a wider population.

Second, due to the potential need of additional contrast medium for the OCT investigation, we excluded patients with chronic kidney disease (CKD) in our study. However, particularly patients with CKD often present with both, increased lesion calcifications and advanced atherosclerosis. Accordingly, we cannot exclude a potential selection bias.

Furthermore, OCT was only performed in the target lesion and 3-vessel OCT was not carried out due to ethical reasons. Thus, comparisons to studies investigating pan-coronary calcification, e.g. using computed tomography is limited.

High-risk characteristics in the diabetic population may be partially influenced by daily glucose fluctuation \[[@CR39]\] and may be found already in patients with an impaired glucose tolerance \[[@CR40]\]. However, in our study we cannot fully exclude impaired glucose tolerance without overt diabetes mellitus in our non-DM group as oral glucose tolerance testing was not performed routinely.

Although our study is to the best of our knowledge currently the largest study quantifying localization, size, shape or extent of calcifications using a quantitative OCT-analysis and comparing diabetic and non-diabetic patients, it is still relatively small and our findings need to be confirmed in larger populations. Furthermore, our study exclusively included patients with stable angina and we therefore cannot draw any conclusions to patients with ACS---this needs to be assessed in future analyses.

Conclusion {#Sec13}
==========

T2DM has an impact on minimal fibrous cap thickness of coronary target lesion in patients with stable CAD, but not on localization, size, shape or extent of calcifications. Thus, the minimal FCT overlying a necrotic lipid core is likely to be the main factor contributing to the increased plaque vulnerability observed in patients with T2DM.
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:   optical coherence tomography
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